Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesbioAffinity Technologies, Inc.

bioAffinity Technologies, Inc.

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
2.6 USD -0.12 ( 4.24%)
Last update at 2026-11-09T17:52:00Z
VOLUME
44972
Market Cap
11.74M

Momentum Score

…

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.59
Low
2.90
High
52 Week Price Range
0.69
Low
15.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information about bioAffinity Technologies, Inc. (NASDAQ: BIAF) is limited; filings identify it as a small-cap company operating in the biomedical/diagnostics sector. Its growth potential could depend on broader trends such as increased demand for cancer diagnostics, aging demographics, and adoption of new diagnostic technologies, which may benefit companies positioned to commercialize effective tests.
Material risks include limited public disclosure and liquidity, dependence on product development and regulatory approvals, potential need for additional financing, and competitive pressures in diagnostics.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.71
Dividend Yield
-
Revenue TTM
6.16M
Revenue Per Share
3.58
Gross Profit TTM
1.94M
Debt / Equity
0.16
ROE
-301.83%
Net Debt
-5.29M
ROCE
-131.26%
Diluted EPS TTM
-8.66

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.87M -9.03M -7.92M -8.15M -6.32M
Net income -14.91M -9.04M -7.94M -8.15M -6.33M
Selling general administrative 9.91M 9.94M 6.79M 2.73M 0.88M
Gross profit 1.43M 3.38M 0.54M 0.00M -0.00M
Reconciled depreciation 0.50M 0.61M 0.11M 0.01M 0.00M
Ebit -10.57M -8.94M -7.97M -4.01M -2.21M
Ebitda -10.07M -8.33M -7.72M -5.82M -1.48M
Depreciation and amortization 0.50M 0.61M 0.25M -1.81M 0.73M
Operating income -10.57M -8.95M -7.97M -4.01M -2.21M
Other operating expenses 16.73M 18.32M 10.51M 4.02M 2.21M
Interest expense 0.04M 0.09M 0.04M 2.53M 1.00M
Tax provision 0.04M 0.01M 0.02M 0.00M 0.00M
Interest income 0.02M 0.02M 0.15M 0.05M 0.00M
Net interest income -0.02M -0.07M 0.05M -2.49M -1.00M
Income tax expense 0.04M 0.01M 0.02M 0.00M 0.00M
Total revenue 6.16M 9.36M 2.53M 0.00M 0.00M
Total operating expenses 12.00M 12.33M 8.52M 4.02M 2.21M
Cost of revenue 4.73M 5.98M 1.99M 0.00M 0.00M
Total other income expense net -4.29M -0.08M 0.06M -4.14M -4.12M
Net income from continuing ops -14.91M -9.04M -7.24M -8.15M -6.33M
Net income applicable to common shares - - - - -6.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.96M 6.51M 8.22M 12.18M 1.45M
Intangible assets 0.72M 0.78M 0.83M - -
Other current assets 0.52M 0.42M 0.32M 0.12M 0.00M
Total liab 3.68M 3.91M 3.37M 1.14M 17.24M
Total stockholder equity 7.28M 2.60M 4.86M 11.04M -15.79M
Deferred long term liab - - - - 0.01M
Other current liab 1.72M 1.40M 1.15M 0.54M 1.60M
Common stock 0.03M 0.11M 0.07M 0.06M 0.02M
Capital stock 0.03M 0.11M 0.07M 0.06M 0.02M
Retained earnings -68.55M -53.64M -44.60M -36.67M -28.51M
Good will 1.40M 1.40M 1.40M - -
Other assets - - - - 0.01M
Cash 6.45M 1.11M 2.82M 11.41M 1.36M
Total current liabilities 2.91M 3.10M 2.25M 1.14M 13.04M
Current deferred revenue 0.04M 0.02M 0.03M - -
Net debt -5.29M 0.40M -1.24M -11.16M 10.00M
Short term debt 0.38M 0.69M 0.46M 0.25M 11.20M
Short long term debt 0.11M 0.17M - 0.25M 11.20M
Short long term debt total 1.16M 1.50M 1.58M 0.25M 11.36M
Other stockholder equity 75.80M 56.14M 49.39M -12134.47M 12.70M
Property plant equipment - - - - 0.00M
Total current assets 7.57M 2.70M 3.97M 11.96M 1.44M
Net tangible assets - - - - -15.79M
Net receivables 0.54M 1.14M 0.81M 0.01M 0.00M
Long term debt 0.04M 0.02M - - 0.16M
Inventory 0.05M 0.03M 0.02M 0.01M 0.07M
Accounts payable 0.76M 0.99M 0.60M 0.35M 0.23M
Non currrent assets other 0.01M 0.02M 0.02M 0.01M 0.01M
Non current assets total 3.40M 3.82M 4.25M 0.22M 0.02M
Capital lease obligations 1.01M 1.31M 1.58M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.08M -2.44M -0.22M 0.00M
Change to liabilities - - - - 0.04M
Total cashflows from investing activities -0.06M -0.08M - - -
Net borrowings -0.37M -0.17M - - 3.51M
Total cash from financing activities 14.73M 5.63M -0.34M 14.34M 3.33M
Change to operating activities - - - - 0.59M
Net income -14.91M -9.04M -7.94M -8.15M -6.33M
Change in cash 5.34M -1.72M -8.59M 10.05M 1.28M
Begin period cash flow 1.11M 2.82M 11.41M 1.36M 0.08M
End period cash flow 6.45M 1.11M 2.82M 11.41M 1.36M
Total cash from operating activities -9.33M -7.26M -6.04M -4.07M -2.05M
Issuance of capital stock 12.06M 4.35M 0.00M 6.03M 0.00M
Depreciation 0.50M 0.61M 0.25M 0.01M 0.00M
Other cashflows from investing activities -0.06M -0.08M - - -
Dividends paid - - - 0.00M -
Change to inventory -0.03M -0.01M -0.01M -0.01M 0.00M
Change to account receivables 0.60M -0.33M 0.31M -0.01M -
Sale purchase of stock - - - -0.00M -
Other cashflows from financing activities 14.73M 1.45M -0.34M 9.01M 6.83M
Change to netincome - - - - 3.16M
Capital expenditures 0.06M 0.08M 0.02M 0.22M 0.00M
Change in working capital 0.59M 0.18M 0.90M 0.11M 0.63M
Stock based compensation 0.67M 0.99M 0.75M 0.25M 0.04M
Other non cash items 4.48M 0.99M 0.96M 3.71M -0.24M
Free cash flow -9.39M -7.34M -6.06M -4.29M -2.05M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BIAF
bioAffinity Technologies, Inc.		 -0.12
4.24%		 2.60 - - 1.91 1.67 1.12 -0.21
TMO
Thermo Fisher Scientific Inc		 12.74
1.83%		 707.50 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.52
1.53%		 233.77 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -0.93
3.65%		 24.52 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 1.01
4.03%		 26.02 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

3300 Nacogdoches Road, San Antonio, TX, United States, 78217

210 698 5334

https://bioaffinitytech.com

57

Name Title Year Born
Ms. Maria Zannes J.D. Founder, Pres, CEO & Director 1956
Dr. Vivienne I. Rebel M.D., Ph.D. Exec. VP and Chief Medical & Science Officer 1965
Mr. Michael Edwards CPA, M.B.A. Chief Financial Officer 1967
Mr. Xavier T. Reveles M.S. VP of Operations NA
Mr. Timothy P. Zannes J.D. Exec. VP, Sec. & Gen. Counsel 1953
Dr. William Bauta Ph.D. Sr. VP of Therapeutics NA
Mr. Steven Girgenti Founder & Executive Chairman of the Board 1946
Ms. Maria Zannes J.D. Founder, President, CEO & Director 1956
Mr. Michael Dougherty C.P.A., M.B.A. VP & CFO 1979
Mr. Xavier T. Reveles M.S. Chief Operating Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…